SCHEMBL3976944

SCHEMBL3976944

CC(=O)Nc1cccc(CC(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.61
SELP P16109 2/20 0.60
SELE P16581 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
HPSE Q9Y251 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.56
CYP1A2 P05177 1/20 0.56
SELL P14151 1/20 0.56
RAB9A P51151 2/20 0.56
POLB P06746 1/20 0.56
NR4A1 P22736 1/20 0.56
NAPRT Q6XQN6 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TSHR P16473 1/20 0.54
NLRP3 Q96P20 1/20 0.52
ENPP2 Q13822 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10391003 0.88 ALDH1A1 (0.58) NPSR1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL5037396 0.85 ALDH1A1 (0.57) NPSR1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL1697114 0.83 ENPP2 (0.60) NR1H4SELPSELEHPSEKMT2A
SCHEMBL30489996 0.83 SLC7A5 (0.55) NPSR1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL15006319 0.83 NPSR1 (0.54) NPSR1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL17653723 0.83 SLC7A5 (0.55) NPSR1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL10752853 0.83 MEN1 (0.61) NR1H4NPSR1MEN1KMT2AALDH1A1
SCHEMBL11628807 0.83 HPSE (0.65) NR1H4SELPSELEHPSEMEN1
SCHEMBL15834247 0.83 L3MBTL1 (0.59) SELPSELENPSR1MEN1KMT2A
SCHEMBL11626346 0.83 SELP (0.65) NR1H4SELPSELEHPSEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243208-A2 PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF HOVIONE - FARMACIÊNCIA, SA (PT) 2025-11-27 WO claimed
WO-2025243208-A2 PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF HOVIONE - FARMACIÊNCIA, SA (PT) 2025-11-27 WO disclosed
WO-2025108986-A1 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2025-05-30 WO disclosed
US-20240199638-A1 GLUTARIMIDES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
CN-118108706-A Glutarimide C4医药公司 2024-05-31 CN disclosed
CN-111278815-B Glutarimide C4医药公司 2024-03-08 CN disclosed
US-11802131-B2 Glutarimides for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-31 US disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 CN disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 WO disclosed
CN-1158256-C Pyrrolidine derivatives-CCR-3 receptor antagonists - 2004-07-21 CN disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed
CN-1331677-A Pyrrolidine derivatives-CCR-3 receptor antagonists HOFFMANN LA ROCHE (CH) 2002-01-16 CN disclosed
EP-1131288-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP disclosed
US-6166015-A Pyrrolidine derivatives-CCR-3 receptor antagonists SYNTEX (U.S.A.) INC. (US) 2000-12-26 US disclosed
WO-2000031032-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO disclosed
US-4067726-A 3-Ureido phenylacetamide herbicides BAYER AKTIENGESELLSCHAFT (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL NR1H4 168/4885SELP 2772/4885SELE 3490/4885
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 NR1H4 3891/4885SELP 4870/4885SELE 4844/4885
US-11802131-B2 Glutarimides for medical treatment CRBN, GCDH, GCLC NR1H4 1424/4885SELP 4829/4885SELE 4659/4885
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof CDK9, CDK7, CDK8 NR1H4 2917/4885SELP 4763/4885SELE 4814/4885
US-20240199638-A1 GLUTARIMIDES FOR MEDICAL TREATMENT CRBN, GCDH, GCLC NR1H4 1424/4885SELP 4829/4885SELE 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.